Citizens Jmp Reaffirms Market Perform Rating for Phreesia (NYSE:PHR)

Phreesia (NYSE:PHR)‘s stock had its “market perform” rating restated by equities research analysts at Citizens Jmp in a research note issued to investors on Wednesday, MarketBeat Ratings reports.

A number of other research firms have also commented on PHR. BMO Capital Markets cut their price objective on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday. Robert W. Baird reaffirmed a “neutral” rating and set a $10.00 target price (down from $25.00) on shares of Phreesia in a report on Tuesday. Canaccord Genuity Group lowered their target price on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday. Royal Bank Of Canada initiated coverage on shares of Phreesia in a report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price target for the company. Finally, Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Twelve investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Phreesia Price Performance

Shares of NYSE PHR opened at $8.35 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $32.76. The stock has a market cap of $503.18 million, a PE ratio of 278.20 and a beta of 0.86. The stock has a fifty day moving average of $12.07 and a 200-day moving average of $17.44.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The company had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. During the same period last year, the company posted ($0.11) EPS. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Equities research analysts anticipate that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other news, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $107,452.17. Following the sale, the insider owned 834,632 shares in the company, valued at approximately $14,197,090.32. This trade represents a 0.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Linetsky sold 6,106 shares of Phreesia stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $103,863.06. Following the sale, the insider directly owned 231,723 shares of the company’s stock, valued at $3,941,608.23. This represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 70,358 shares of company stock worth $1,123,569 over the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

Several institutional investors have recently modified their holdings of the company. Granahan Investment Management LLC lifted its position in Phreesia by 73.8% in the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after purchasing an additional 1,018,987 shares during the last quarter. Prosight Management LP bought a new position in shares of Phreesia in the fourth quarter worth approximately $16,533,000. Millennium Management LLC grew its holdings in shares of Phreesia by 730.7% in the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after purchasing an additional 936,033 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Phreesia in the fourth quarter worth $15,213,000. Finally, Greenhouse Funds LLLP increased its stake in shares of Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after buying an additional 557,265 shares during the period. 92.10% of the stock is currently owned by institutional investors.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analyst take: a MarketBeat piece argues Phreesia may have hit a trough and is well‑positioned to regain growth and market share over time, suggesting upside if execution and demand stabilize. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several large firms have issued neutral/market‑perform ratings (Robert W. Baird, JPMorgan, Citigroup), signaling limited near‑term conviction rather than outright sell ratings. Phreesia (NYSE:PHR) Earns “Neutral” Rating from Robert W. Baird
• Neutral Sentiment: Citizens JMP reaffirmed a market‑perform view, reflecting tepid near‑term expectations from another sell‑side firm. Citizens JMP Market Perform Reaffirmed
• Neutral Sentiment: Investor comparison coverage contrasts Phreesia with peers (MSP Recovery), providing context but not a clear directional trigger. Phreesia and MSP Recovery Critical Contrast
• Negative Sentiment: Primary catalyst: Phreesia reported its first full‑year profit but issued lower FY2027 revenue guidance, prompting a sharp selloff as investors focused on the reduced top‑line outlook. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: Multiple analysts cut expectations and targets (Canaccord cut its price target to $22; Needham, Stephens and BMO issued more pessimistic views), increasing selling pressure and lowering implied valuation. Needham Lowers Expectations for Phreesia BMO Capital Markets Issues Pessimistic Forecast for Phreesia Needham & Company LLC Has Lowered Expectations for Phreesia
• Negative Sentiment: The stock hit a new one‑year low after the earnings/guide miss, a technical signal that can accelerate outflows from momentum and quant funds. Phreesia Reaches New 1-Year Low After Earnings Miss
• Negative Sentiment: Legal risk: a law firm announced an investigation into potential securities‑law violations tied to prior guidance comments, adding uncertainty and potential headline risk. Investors in Phreesia Warned of Potential Securities Fraud
• Negative Sentiment: Some outlets and analysts pulled recommendations or expressed disappointment in growth guidance, reinforcing negative sentiment. Phreesia’s growth guidance disappointed. We’re pulling our recommendation.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.